Open AccessPosterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small‐cell lung cancer
Author(s) -
Kim Dohhyung
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2122
Subject(s) - medicine , posterior reversible encephalopathy syndrome , nivolumab , cerebral edema , encephalopathy , lung cancer , immunotherapy , brain edema , cancer , magnetic resonance imaging , radiology
Key Clinical Message Posterior reversible encephalopathy syndrome ( PRES ) is a neurological syndrome characterized by vasogenic cerebral edema with predominantly posterior involvement. Uncontrolled severe hypertension and endothelial dysfunction have been implicated as two main mechanisms. Clinicians should notice the development of PRES in hypertensive patients accompanying neurological changes, such as impaired vision and consciousness.